On May 25, 2023, Oppenheimer maintained coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with an Outperform recommendation, as reported by Fintel.
The average one-year price target for Cyclacel Pharmaceuticals as of May 11, 2023 is 13.77, with a high of $19.95 and a low of 8.08. The average price target indicates a potential increase of 1,955.22% from its latest reported closing price of 0.67.
According to Fintel’s leaderboard of companies with the largest price target upside, Cyclacel Pharmaceuticals has significant potential for growth.
The projected annual revenue for Cyclacel Pharmaceuticals is $0MM, down 100.00%. Similarly, the projected annual non-GAAP EPS is -2.02.
There are 37 funds or institutions reporting positions in Cyclacel Pharmaceuticals, a decrease of 3 owners or 7.50% in the last quarter. The average portfolio weight of all funds dedicated to CYCC is 0.00%, a decrease of 19.18%. Total shares owned by institutions increased in the last three months by 2.18% to 2,635K shares.
The put/call ratio of CYCC is 0.01, indicating a bullish outlook. This is further confirmed by the various shareholders who have increased their stakes in the company, such as Ikarian Capital, which reported owning 275K shares, representing an increase of 100.00%.
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing innovative medicines using its expertise in cell cycle, transcriptional regulation, and DNA damage response biology in cancer cells. Cyclacel’s pipeline aims to build a diversified biopharmaceutical business focused on hematology and oncology by introducing novel drug candidates.
This article originally appeared on Fintel and may contain the views and opinions of the author, and not necessarily those of Nasdaq, Inc.
